Clinical Trial Update: A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 [Phase 3]

View source ↗

Summary

Phase 3 trial update for ALKS 8700 in adults with relapsing-remitting multiple sclerosis (EVOLVE-MS-1) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ALKS 8700 (ALKS 8700)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2022-06-24